论文部分内容阅读
目的:观察应用OsteoSet骨移植替代品修复骨肿瘤性骨缺损的临床疗效。方法:选择2004-06/2006-09吉林大学第一医院采用OsteoSet骨移植替代品修复骨肿瘤性骨缺损患者22例,患者及家属均知情同意。将肿瘤彻底刮除或切除,残腔刮除干净,干纱布填塞止血,灭活,然后将OsteoSet骨移植替代品(由美国Wright公司研究生产,以医用硫酸钙为基质,具有高纯度的α晶体结构,不透X射线,可以使血管和骨生成细胞长入,同时可被生物降解)放入要填充骨骼的治疗部位,所有骨缺损需填满。修复术后定期复查X射线片,计算颗粒吸收率和新骨生长率,颗粒吸收率=颗粒吸收区域面积/骨缺损总面积×100%;新骨生长率=新骨生成区域/骨缺损总面积×100%。同时对患者进行随访,了解其肢体功能恢复情况及并发症发生情况。结果:①22例患者均得到随访,随访6～9个月,其中随访6,7,8,9个月者分别为8,6,3及5例。术后所有患者OsteoSet骨移植替代品吸收良好,没有出现不良反应;缺损区新骨长入良好;患者肢体功能恢复良好,其中1例患者发生骨折。②术后12周97.1%的OsteoSet骨移植替代品颗粒被吸收,95.3%的新骨长入缺损区;术后6个月99.1%的OsteoSet骨移植替代品颗粒被吸收,98.6%的新骨长入缺损区。结论:OsteoSet骨移植替代品自然吸收率与新骨生长率基本一致,是一种理想的骨缺损充填材料。
Objective: To observe the clinical effect of OsteoSet bone substitute in the repair of bone tumor bone defects. Methods: Twenty-two patients with bone tumor bone defects repaired with OsteoSet bone graft substitute were selected from the First Hospital of Jilin University from June 2004 to September 2006, with informed consent of patients and their families. The tumor was completely removed or resected, the residual cavity was removed, the dry gauze was stuffed to stop bleeding, inactivated, and OsteoSet bone graft substitute (produced by Wright Company in the United States, based on medical calcium sulfate, with high purity alpha crystal The structure, radiopaque, allows blood vessels and osteogenic cells to grow, while being biodegradable) into the treatment site where the bone is to be filled, all bone defects to be filled. X-ray films were regularly reviewed after repair. The rate of particle absorption and new bone growth was calculated. The rate of particle absorption = the area of the particle absorption area / the total area of the bone defect × 100%. The growth rate of the new bone = the total area of the new bone formation area / × 100%. At the same time, patients were followed up to understand the recovery of limb function and complications. Results: All the 22 patients were followed up for 6 to 9 months, of which 8, 6, 3 and 5 were followed up for 6, 7, 8 and 9 months respectively. All patients received postoperative OsteoSet bone graft surrogate well absorbed, no adverse reactions; defect of new bone grow well; function recovery of patients with limbs, including 1 case of fracture. ② At 12 weeks after operation, 97.1% of OsteoSet bone graft substitutes were absorbed and 95.3% of new bone grew into the defect area. Six months later, 99.1% of OsteoSet bone graft substitutes were absorbed and 98.6% Into the defect area. CONCLUSIONS: OsteoSet bone graft substitutes naturally absorb rate is basically the same as new bone growth rate, which is an ideal bone defect filling material.